Full text
Earnings transcript
Read the complete earnings call transcript.
VRTX
Vertex Pharmaceuticals Incorporated
$438.71
-8.55
(-1.91%)
| Exchange: | NASDAQ |
| Market Cap: | 111.432B |
| Shares Outstanding: | 13.03M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Reshma Kewalramani | |||||
| Full Time Employees: | 6100 | |||||
| Address: |
| |||||
| Website: | https://www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 9,869,200 | 11,020,100 | 12,074,600 |
| Gross Profit | 8,607,000 | 9,489,600 | 10,267,500 |
| EBITDA | 4,605,200 | 486,300 | 4,967,900 |
| Operating Income | 3,832,000 | -232,900 | 4,760,700 |
| Net Income | 3,619,600 | -535,600 | 3,953,200 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 22,730,200 | 22,533,200 | 25,643,000 |
| Total Liabilities | 5,149,800 | 6,123,600 | 6,977,200 |
| Total Stockholders Equity | 17,580,400 | 16,409,600 | 18,665,800 |
| Total Debt | 808,400 | 1,749,500 | 3,693,000 |
| Cash and Cash Equivalents | 10,369,100 | 4,569,600 | 5,084,800 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 3,537,300 | -492,600 | 3,631,400 |
| Capital Expenditure | -258,399.999 | -297,700 | -437,600 |
| Free Cash Flow | 3,278,900.001 | -790,300 | 3,193,800 |
| Net Income | 3,619,600 | -535,600 | 3,953,200 |
| Net Change in Cash | -139,700 | -5,800,100 | 515,600 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 18,642,759.987 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 21,437,041.236 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 19,779,347.733 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 6,726,391.437 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 7,734,580.647 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 7,136,477.395 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 7,963,428.030 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 9,544,023.756 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 8,606,343.393 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,274,137.414 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,614,997.862 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,412,784.090 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 33.360 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 36.990 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 30.870 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 11 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Vertex Pharmaceuticals reported strong financial results in Q4 2024, with revenue and net income growth exceeding expectations, as highlighted in the earnings call transcript. Key metrics such as operating cash flow and free cash flow demonstrate solid liquidity and operational efficiency, supporting sustained growth.
- Innovative Product Pipeline: The company emphasized advancements in its clinical pipeline during the Q4 2024 earnings call, with new product launches contributing to revenue growth. This focus on innovation aligns with industry trends in biotechnology, positioning VRTX as a leader in its sector.
- Strong Profitability Metrics: High gross profit margin and net profit margin (TTM) reflect efficient cost management and profitability compared to industry averages, providing a competitive edge within the biotechnology sector.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about VRTX valuation
Is Vertex Pharmaceuticals Incorporated (VRTX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Vertex Pharmaceuticals Incorporated (VRTX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is VRTX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether VRTX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is VRTX’s P/E ratio?
You can see VRTX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for VRTX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is VRTX a good long-term investment?
Whether VRTX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
VRTX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.91
Trading Metrics:
| Open: | 444.54 | Previous Close: | 447.26 | |
| Day Low: | 436.56 | Day High: | 449.62 | |
| Year Low: | 362.5 | Year High: | 510.77 | |
| Price Avg 50: | 467.89 | Price Avg 200: | 438.32 | |
| Volume: | 1.243M | Average Volume: | 1.382M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeVRTX full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Vertex Pharmaceuticals, ticker VRTX, a powerhouse in the biotech space. If you’re looking to invest in a company that’s been making waves with its innovative therapies, stick around because we’re breaking down everything from financials to future potential. Let’s get started! So, why are we talking about Vertex Pharmaceuticals? Well, this isn’t just any biotech company—it’s a leader in developing treatments for serious diseases,…
